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Human cathelicidin-derived LL-37 is a 37-residue cationic, amphipathic α-helical peptide. It is an active component of mammalian innate
immunity. LL-37 has several biological functions including a broad spectrum of antimicrobial activities and LPS-neutralizing activity. In order to
determine the high-resolution three-dimensional structure of LL-37 using NMR spectroscopy, it is important to obtain the peptide with isotopic
labels such as 15N, 13C and/or 2H. Since it is less expensive to obtain such a peptide biologically, in this study, we report for the first time a method
to express in E. coli and purify LL-37 using Glutathione S-transferase (GST) fusion system. LL-37 gene was inserted into vector pGEX-4T3 and
expressed as a GST-LL-37 fusion protein in BL21(DE3) strain. The recombinant GST-LL-37 protein was purified with a yield of 8 mg/l by affinity
chromatography and analyzed its biochemical and spectroscopic properties. Factor Xa was used to cleave a 4.5-kDa LL-37 from the GST-LL-37
fusion protein and the peptide was purified using a reverse-phase HPLC on a Vydac C18 column with a final yield of 0.3 mg/l. The protein purified
using reverse-phase HPLC was confirmed to be LL-37 by the analyses of Western blot and MALDI-TOF-Mass spectrometry. E. coli cells
harboring the expression vector pGEX-4T3-LL-37 were grown in the presence of the 15N-labeled M9 minimal medium and culture conditions
were optimized to obtain uniform 15N enrichment in the constitutively expressed LL-37 peptide. These results suggest that our production method
will be useful in obtaining a large quantity of recombinant LL-37 peptide for NMR studies.
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Increasing resistance of virtually all microbes toward
common antibiotics that have provided safety for the last half
a century is a major concern presently in the health science.
Natural antimicrobial peptides probably represent one of the
very first evolved forms of chemical defense of living
eukaryotic cells against invasion by other living organisms
[1,2]. Antimicrobial peptides have survived in this role over
evolutionary time scales, likely due to the fact that they are less
susceptible to the development of bacterial resistance because
they disrupt the membrane of bacteria through non-specific
peptide–lipid interactions. These peptides show a broad⁎ Corresponding author. Tel.: +1 734 647 6572; fax: +1 734 764 3323.
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doi:10.1016/j.bbamem.2006.02.003spectrum of antimicrobial activities against Gram-negative
and Gram-positive bacteria, and fungi.
LL-37 is an antimicrobial peptide with 37 amino acid
residues found in human and has been shown to play a vital role
in innate immunity. It is a 4.5-kDa cationic, amphipathic α-
helical peptide derived from the cathelicidin protein [3]. Since
LL-37 is the only human antimicrobial peptide in the
cathelicidin family and shows a broad spectrum of antimicrobial
activity [4,5], there is a significant interest in developing this
peptide for pharmaceutical applications. It is initially expressed
as a 18 kDa human cathelin-associated protein (hCAP18), and
the 14-kDa N-terminal cathelin-like domain that binds and
sequesters the peptide [6] must be removed in order for LL-37
to become active. In addition to its antimicrobial activity, it has
been reported to be chemotactic for monocytes, T lymphocytes,
neutrophils, and mast cells [7,8], and capable of modulating the
expression profile of chemokines, chemokine receptors, and
additional genes in macrophages and other mammalian cells [9].
More recently, LL-37 has been found to have additional
defensive roles: binding and neutralizing LPS [10–14],
Table 1
Components of 1L of supplemented minimal medium for the production of 15N
labeled LL-37
Per liter
(1) 985 ml of M9 minimal medium, pH 7.4 (autoclaved)
Na2HPO4 6.0 g
KH2PO4 3.0 g
NaCl 0.5 g
(2) 0.5 ml of trace elements (sterile filtered)
CuSO4•7H2O 6.0 g
NaI 0.08 g
MnSO4•H2O 3.0 g
Na2MoO4•2H2O 0.2 g
H3BO3 0.02 g
CoCl2 0.5 g
ZnCl2 20.0 g
FeSO4•7H2O 65.0 g
Biotin 0.2 g
H2SO4 5.0 ml
(3) 1g 15NH4Cl/10 ml sterile dH2O (sterile filtered)
(4) 10 ml of 20% (w/v) D-glucose (sterile filtered)
(5) 2 ml of 1.0 M MgSO4 (autoclaved)
(6) 1 ml of ampicilin (100 mg/ml)
1352 J.-Y. Moon et al. / Biochimica et Biophysica Acta 1758 (2006) 1351–1358promoting re-epithelialization and wound closure [15], regu-
lating the inflammatory response [16–18] and chemoattracting
cells of the adaptive immune system to wound or infection sites
at concentrations below the levels required for antimicrobial
activity [7,19,20].
Recent studies have shown that LL-37 functions via the
bacterial membrane-disruption by interacting with phospholi-
pids of the membrane [21,22]. However, understanding the
detailed mechanism of lipid bilayer disruption, oligomeric
nature of LL-37 in a membrane environment, and the three-
dimensional structure of the peptide will be highly valuable.
Since the peptide is structured and oligomerized in solution as
well as in membranes, structure of the peptide determined using
solution and solid-state NMR experiments would be effective
tools for deciphering such a mechanism to a high degree of
resolution. However, large quantities (tens of milligrams) of
pure recombinant peptide labeled with isotopes are required for
such studies. In order to provide large quantities of these
peptides for physiological and structural investigations, suitable
production methods are necessary. Antimicrobial peptides with
a short length of amino acid sequence can be prepared by a solid
phase chemical synthesis, but could be very expensive
particularly for obtaining a large quantity of labeled peptide.
On the other hand, recombinant methods permit the production
of peptides and proteins in microorganisms. We report for the
first time a method to express and purify LL-37 using
Glutathione S-transferase (GST) fusion system. In this study,
the E. coli strain, BL21 (DE3), and GST fusion partner were
used to produce the recombinant LL-37, both unlabeled and
labeled with 15N. An E. coli expression system was constructed
for production of the peptide and a large-scale purification was
developed. In this study, we show that the expression of LL-37
can be facilitated by the hCAP18 and considerable amounts of
LL-37 can be obtained by this efficient purification method.
2. Materials and methods
2.1. Materials
The cDNA of LL-37 and expression vector pGEX-4T3 were generously
provided by Dr. Ole Sorensen, Lund University, Lund, Sweden. Host cell E. coli
BL21(DE3) strain and Factor Xa were purchased from Novagen (Madison,
Wisconsin). Restriction endonucleases, BamHI and EcoRI, were from
GibcoBRL Life Technologies. T4 DNA ligase was also from Promega. Plasmid
extraction kit was from Qiagen. Acrylamide, bisacrylamide, SDS, and Tricine
were from Bio-Rad. GSTrap FF column and thrombin were from Amersham
Biosciences Corp. 15NH4Cl was purchased from Cambridge Isotope Labora-
tories. Rabbit IgG anti-LL-37 antibody was generously provided by Dr. Birgitta
Agerberth, Karolinska Institute, Stockholm, Sweden.
2.2. Construction of the pGEX-LL-37 expression vector
The expression vector pGEX-4T3-LL37 was constructed in the laboratory of
Dr. Ole E. Sorensen. A Factor Xa cleavage site was inserted to the N-terminal of
the cDNA of LL-37. It encodes 26-kDa glutathione S-transferase of Schistosoma
japonicum and the amino acids of LL-37, connected by site-specific recognition
sequences for both thrombin and Factor Xa. The expression vector pGEX-4T3-
LL-37 was transformed to E. coli JM109 competent cells and screened in LB
medium containing ampicillin (100 μg/ml). The expression vector was
confirmed on an agarose gel after double digestions with BamHI and EcoRI
and further confirmed by DNA sequencing using the primer with a sequence:GGG CTG GCA AGC CAC GTT TGG TG. Finally, the successfully
constructed expression vector pGEX-4T3-LL37 was then used to transform to
E. coli strain BL21(DE3) competent cells (Novagen) for expression purpose and
transformants were selected by growth on Luria–Bertani (LB)/ampicillin plates.
The positive clone harboring the recombinant plasmid was designed as BL21-
GST-LL-37.
2.3. Expression of GST-LL-37 fusion protein
A 100 ml culture on a standard M9 minimal growth media supplemented
with 100 μg/ml ampicillin was started by inoculating single E. coli BL21-GST-
LL-37 colony, and agitated for ∼16 h at 250 rpm at 30 °C to OD600 nm of ∼1.0.
For GST-LL-37 expression, the bacteria were diluted (1:10) into standard M9
minimal medium and grown at 30 °C until OD600 nm ∼0.7. Protein expression
was induced with 0.1 mM IPTG and cells were harvested after 6 h of incubation
at 30 °C. All cells were harvested by centrifugation at 5000×g for 30 min at 4 °C.
Pellet was washed in 1/20 culture volume of PBS.
The production of the 15N-labeled LL-37 peptide was carried out by
culturing E. coli BL21 (DE3) harboring recombinant expression vector pGEX-
4T3-LL37 in a M9 minimal medium with 15N-labeled ammonium chloride as
the sole nitrogen source. The general protocol for 15N labeling is as follows.
Cells were overnight cultured in 50 ml of M9 minimal growth medium
supplemented with 100 μg/ml ampicillin at 30 °C by shaking at 250 rpm. The
overnight cultured cells were pelleted by a 30-min centrifugation at 5,000×g.
The cells were then washed and pelleted using an M9 minimal growth medium,
excluding all nitrogen sources. The pelleted cells were resuspended in 5 ml of
M9 minimal medium, which includes 15NH4Cl as sole nitrogen source (Table 1).
The resuspended cells were inoculated to 1 l of M9 minimal medium containing
15NH4Cl, then incubated to allow the recovery of growth and clearance of
unlabeled metabolites. Upon reaching optical cell densities at OD600 nm ∼0.7,
protein expression was induced by adding 1 ml of 1M IPTG and 2.5 ml of 20%
(w/v) D-glucose. After a 7-h incubation period the cells were harvested by
centrifugation at 5000×g for 30 min at 4 °C. Pellet was washed in 1/20 culture
volume of PBS.
2.4. Purification of GST-LL-37 fusion protein
The pellet (10 g wet) washed with PBS was resuspended in 100 ml 1× PBS
buffer (pH 7.4) and 5 mMDTT. After addition of a 10 mg lysozyme (Sigma) per
1 g of bacteria, the resuspension was sonicated three times for 15 s at 18 μm
probe using a Sonifier 250 (Branson, output=20) on ice. The suspension was
stirred at room temperature for 2 h followed by the addition of Triton X-100 to a
Fig. 1. Map of the recombinant expression vector pGEX-4T3-LL-37. cDNA of
the human LL-37 (37-amino acids) and Factor Xa cleavage sequence (IEGR)
was inserted into the BamHI and EcoRI sites of pGEX-4T3 downstream from
the GST gene. Expression of the GST-LL-37 fusion protein is controlled by the
tac promoter (Ptac). The vector also contains the ampicillin resistance gene
(Ampr), the pBR322 origin of replication (pBR322 ori), and the lac Iq gene. T
and F denote thrombin and Factor Xa cleavage sites, respectively.
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suspension was ultra-centrifuged at 105,000×g for 1 h to remove cell debris and
other particles. The GST-LL-37 fusion protein from the clear supernatant was
affinity purified using a 1-ml GSTrap FF column, equilibrated in 20 ml ice-cold
binding buffer (1× PBS, pH 7.3) containing 5 mM DTT. The clear supernatant
was loaded to the GSTrap FF column at a flow rate of 0.5 ml/min. The column
was washed with 10 column volumes of 1× PBS, pH 7.4, containing 5 mMDTT
at a flow rate of 1 ml/min to remove unbound proteins. GST-LL-37 was eluted
from the column at 4 °C with 5 volume of elution buffer (50 mM Tris–HCl, pH
8.0, containing 10 mM reduced glutathione and 5 mM DTT). The flow-through
was collected in 0.5 ml fractions and reserved until the procedure has been
successfully completed. The presence and purity of eluted GST-LL-37 was
evaluated by SDS-PAGE using 12% SDS gels.
2.5. Dialysis and Factor Xa cleavage of GST-LL-37 fusion protein
The solution containing GST-LL-37 protein was dialyzed against 400
volumes of Factor Xa cleavage buffer (50 mM Tris–HCl, 150 mM NaCl, and
1 mM CaCl2, pH 7.5) for overnight. For cleavage of LL-37 from GST tag, the
dialyzed GST-LL37 fusion protein solution was incubated with Factor Xa
cleavage buffer plus 80 U Factor Xa for 16–24 h at 21–23 °C. The cleavage
reaction was stopped by freezing the sample at −20 °C. The cleaved protein
solution was applied to a reverse-phase HPLC chromatography to purify LL-37.
2.6. LL-37 purification
The GST-LL-37 protein solution digested by Factor Xa was redissolved in
0.1% (v/v) trifluoroacetic acid/water (2 ml) and injected onto a (10×250 mm)
Vydac C18 reverse-phase HPLC column (Separations Group) equilibrated with
25% acetonitrile containing 0.1% (v/v) trifluoroacetic acid/water at a flow rate of
1.0 ml min−1. The concentration of acetonitrile in the eluting solvent was raised
from 25 to 70% (v/v) with a linear gradient for 60 min. Absorbance was
monitored at 214 nm and fractions (1 min) were collected. The concentration of
LL-37 was determined by comparing its peak area with that of the chemically
synthesized LL-37. The eluted LL-37 was freeze-dried with a BenchTop Freeze
Dryer (VirTis, USA) and re-dissolved in sterile PBS. The molecular weight and
homogeneity of the LL-37 was analyzed by MALDI-Tofspec-2E instrument
(Micromass®, UK) and by SDS-PAGE.
2.7. Quantification and identification of LL-37
Quantification of the recombinant GST-LL-37 was performed by Bradford
assay. Purity of GST-LL-37 protein preparations was analyzed by SDS-PAGE
using 12% SDS gels. The purified LL-37 was analyzed by SDS-PAGE using a
15% Tris–Tricine running gel. SDS-PAGE [23] was performed with Bio-Rad
systems according to the instruction given by the manufacturer (Bio-Rad,
Hercules, CA). The gels were visualized by staining with Coomassie brilliant
blue R250 or by silver staining. For Western blot analysis, proteins on SDS-
PAGE were transferred electrophoretically onto nitrocellulose membrane for 2 h
at 100 V. The membrane was first blocked with 5% (w/v) nonfat dry milk in
TBST (150 mM NaCl, 25 mM Tris, and 0.1% Tween 20, pH 7.5) overnight at 4
°C. Then, the membrane was incubated with diluted rabbit polyclonal LL-37
antibody (1:1000) in 5% nonfat milk TBST for 2 h at room temperature,
followed by incubation with horseradish peroxidase-conjugated anti-rabbit IgG
from monkey (Amersham Biosciences) (1:2000 diluted in 5% nonfat milk
TBST) for another 2 h at room temperature. Detection was performed by
enhanced chemiluminescence (Amersham Biosciences) as described by the
supplier and the light produced was exposed to Hyperfilm ECL (Amersham
Biosciences).
2.8. GST activity assay
The presence of the GST-LL-37 fusion protein was monitored by evaluating
the GST activity in the bacterial extracts using GST-Tag Assay kit (Novagen).
For the detection of enzymatic activity, 1-chloro-2,4-dinitrobenzene (CDNB)
was used as substrate. The GST-mediated reaction of CDNB with glutathione
produces a conjugate that can be monitored by measuring absorbance at 340 nm.Briefly, 880 μl of deionized H2O, 100 μl 1 M potassium phosphate, pH 6.5, and
10 μl 20 mM CDNB in ethanol were mixed and added with 50 μl of 100 mM
reduced glutathione. Absorbance change at 340 nm was measured for 5 min in a
spectrophotometer (Cary 300 Bio) at room temperature. The mass of GST-LL-
37 was calculated from the standard curve.
2.9. MALDI-TOF-MS analysis
The molecular weight and homogeneity of LL-37 were analyzed by a
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometer (Micromass®, UK). Mass spectrometric analysis was performed
on a MALDI-Tofspec-2E instrument (Micromass®, UK) equipped with a pulsed
nitrogen laser emitting at 337 nm. Pressure in the ion chamber was maintained
between 1×10−7 and 4×10−7 Torr. The matrix solution contained 10 mg/ml
sinapinic acid dissolved in 50/50 acetonitrile/water with 0.1% TFA. A 10 μl of
matrix solution was added to the LL-37 vial, spotted on the target, and
evaporated to dryness. The instrument was externally calibrated with a mixture
of α-chain ([M+H]+=3497.0 Da) and β-chain of insulin (M+H]+=5731.6 Da)
in the sinapinic acid matrix. The instrument was operated in reflection mode
with delayed extraction and the accelerating voltage in the ion source was 25 kV.
The accuracy of mass determinations was within 0.02%.
3. Results
3.1. Construction of an expression vector
In this study, we confirmed an expression vector, pGEX-
4T3-LL-37, which would overproduce a protein containing LL-
37, fused to the carboxy-terminus of glutathione S-transferase in
E. coli (Fig. 1). This vector was designed to express human LL-
Table 2
Purification steps of LL-37 from a 1-l culture of E. coli BL21(DE3) harboring
the plasmid pGEX-4T3-LL-37
Purification step Volume
(ml)
Total
protein
(mg)
GST-LL-37
(mg)
LL-37
(mg)
Yield
(%)
Bacterial lysate 50 745 32 4.3 a 100
Soluble fractions
(105,000 g
supernatants)
40 532 19.7 2.6a 60
GSTrap FF affinity
chromatography
20 7.9 7.6 1.0a 24
HPLC(C18 column) 2 0.3 ND
b 0.3 7
The wet weight of cells after IPTG induction for 6 h at 30°C was ≈ 4 g per liter
culture. GST-LL-37 content was estimated by GST activity assay.
a The amount of LL-37 was calculated from the mass ratio compared to the
determined amount of fusion protein.
b Not determined.
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downstream GST encoding DNA in the same open reading
frame by inserting the gene into the BamHI and EcoRI
restriction sites in the multiple cloning sites of pGEX-4T3.
Between GST and LL-37 there were site-specific recognition
sequences, both thrombin and Factor Xa, for the release of intact
LL-37 (Fig. 1). The recombinant plasmid with correct reading
frame was confirmed by DNA sequencing. Expression of the
fusion protein is controlled by the tac promoter.
3.2. Induction of fusion protein expression
The constructed vector was expected to encode a fusion
protein of 287 residues with the expected molecular weight of
33,370 Da. To determine whether pGEX-4T3-LL-37 could
generate the expression of the fusion protein, E. coli BL21 cells
harboring the plasmid were treated with 0.1 mM IPTG. The
expression of a ~33 kDa protein was induced in the presence of
IPTG (Fig. 2, lane 2). The relative migration of the new protein
corresponds to that predicted for a fusion between LL-37 (MW
of 4.5 kDa) and GST (MW of ∼29 kDa). The amount of the
expressed fusion protein was estimated to be 15–30% of the
total protein in E. coli BL21 harboring pGEX-4T3-LL-37
plasmid as judged from Coomassie Blue staining (Fig. 2). These
results show that E. coli BL21 harboring pGEX-4T3-LL-37
plasmid expresses recombinant GST-LL-37 fusion protein as
expected.
3.3. Purification of GST-LL-37
Both the unlabeled and 15N-labeled GST-LL-37 fusion
proteins were purified from the supernatants of cell lysates
using a 1 ml GSTrap FF (Amersham Biosciences) column
equilibrated with binding buffer. Elution with reduced glutathi-
one buffer yielded over 8 mg/l of culture of GST-LL-37 at >95%
purity (Fig. 2, lane 5 and Table 2). Intense bands correspondingFig. 2. SDS-PAGE of a recombinant GST-LL-37 fusion protein purified at
different stages of the procedure given in Table 1. GST-LL-37 was purified from
E. coli BL21 using a glutathione affinity chromatography. Lane 2 is the extract
of IPTG-induced E. coli BL21 (DE3) containing the expression vector pGEX-
4T3. Lanes 3 and 4 are the solubilized supernatant of IPTG-induced E. coli
BL21 (DE3) with Triton X-100 and the supernatant ultra-centrifuged at
10,5000×g, respectively. Lanes 5 and 6 are the recombinant GST-LL-37 purified
using GSTrap FF column chromatography and synthetic LL-37, respectively.
Both lanes 1 and 7 are protein molecular weight markers (kDa).to the molecular weights of the expected proteins were shown:
29 kDa for GST and 33 kDa for GST-LL-37. The presence of a
band at 29 kDa size may be caused by intracellular cleavage of
the fusion protein, or by translational pausing at the junction
between GST and the fusion partner. Excessive sonication in the
step of cell lysate preparation may also lead to denaturation and
breakdown of the fusion protein, which results in the appearance
of a band at 29 kDa size. The recombinant GST-LL-37 fusion
protein expressed in this condition was from soluble fractions,
not from inclusion bodies. The recombinant protein was further
confirmed by Western blot using LL-37 antisera raised from
rabbit as shown in Fig. 3. The result showed a strong band at a
molecular weight of 33 kDa, confirming that E. coli BL21 strain
harboring pGEX-4T3-LL-37 vector expressed recombinant
GST-LL-37 fusion protein as expected.
3.4. Production of recombinant LL-37
The GST-LL-37 fusion protein sequentially consisted of the
following regions from its N-terminus: the GST domainFig. 3. Western blot analysis of a recombinant GST-LL-37 at different stages of
purification procedure and GST-LL-37 digested with Factor Xa or thrombin.
After the samples were run on 15% Tris–Tricine SDS-PAGE gel, and transferred
to nitrocellulose membrane, the proteins were immunodetected using LL-37
antibody. Lane 1: E. coli BL21-GST-LL-37 cell extracts; lane 2: supernatants
(105,000 g fractions) of cell extracts; lane 3: purified GST-LL-37 fusion protein;
lane 4: GST-tag protein; lane 5: GST-LL-37 fusion protein digested with 1 U
Factor Xa; lane 6: GST-LL-37 fusion protein digested with 2 U thrombin; lane 7:
LL-37 purified from GSTrap FF on-Column cleavage; lane 8: synthetic LL-37.
Fig. 4. Purification of a recombinant LL-37 by reverse-phase HPLC on a Vydac
C18 column and Tris–Tricine SDS-PAGE analysis of the purified fractions. (A)
Reverse-phase HPLC chromatogram. GST-LL-37 solutions after digestion by
Factor Xa were concentrated, and applied on a Vydac C18 column (10×250 mm)
previously equilibrated with 0.1% TFA. The digested solutions were eluted from
the column with a linear gradient from 25 to 70% acetonitrile in 0.1% TFA. (B)
Tris–Tricine SDS-PAGE analysis. Fractions of peaks 1, 2, 3 and 4 were loaded
on lanes 1, 2, 3 and 4 of 15% Tris–Tricine SDS-PAGE gel, respectively. These
fractions were identified as GST, GST-LL37, a mixture of GST-LL-37 and LL-
37, and LL-37, respectively.
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sites (6 residues), Factor Xa cleavage site (4 residues), and the
LL-37 domain (37 residues). Thus, the fusion protein was
expressed with 287 amino acid residues which correspond to the
molecular weight of 33,370 Da as expected. The recombinant
LL-37 peptide can be harvested from the fusion proteins by the
cleavage with either Factor Xa or thrombin. Western blot
analysis, after SDS-PAGE using a 15% Tris–Tricine running
gel and its transfer to nitrocellulose membrane, confirmed the
presence of recombinant LL-37 with different molecular size
from the two-enzymatic digestions as expected (Fig. 3, lanes 5
and 6). The recombinant LL-37 peptide was first cleaved from
their GST fusion proteins by enzymatic digestion with various
concentrations of Factor Xa. The efficiency of this reaction was
50% cleavage using 10 U of Factor Xa/mg of the fusion protein
at 22 °C for 16–24 h (data not shown). The result showed that
one single band corresponding to approximately 4.5 kDa, the
same size as the chemically synthesized LL-37, was observed
under the Western blot analysis (Fig. 3, lane 5). As pGEX-4T3
vector contains one thrombin site, the recombinant LL-37
peptide was also obtained from the GST-LL-37 fusion protein
by enzymatic digestion with thrombin (Fig. 3, lane 6). Thus, the
recombinant LL-37 peptide obtained by enzymatic digestion
with thrombin showed a longer size than that of chemically
synthesized LL-37 as expected. Production of the longer size of
recombinant peptide by the digestion with thrombin was from
the presence of the 6 extra amino acid residues, Gly–Ile–Ile–
Glu–Gly–Arg, at the N-terminus of LL-37. Western blot
analysis, after SDS-PAGE using a 15% Tris–Tricine running
gel and its transfer to nitrocellulose membrane, confirmed the
presence of recombinant LL-37 with different molecular size
from the two-enzymatic digestions as expected (Fig. 3, lanes 5
and 6).
3.5. Purification of recombinant LL-37
The recombinant LL-37 peptide from the cleavage products
with Factor Xa was purified by applying the cleavage product
to reverse-phase HPLC on a Vydac C18 column (Fig. 4A). All
the eluted fractions were analyzed on a 15% Tris–Tricine
SDS-PAGE gel (Fig. 4B). The fraction eluted at 43 min of
retention time contained a single band with an apparent
molecular weight of 4.5 kDa, suggesting as LL-37. The
fraction eluted at 41 min of retention time contained both LL-
37 and GST-LL-37. The fractions at peaks 1–4 were identified
as GST-tag, GST-LL-37, a mixture of GST-LL-37 and LL-37,
and LL-37, respectively. The identity of LL-37 was confirmed
by MOLDI-TOF mass spectrometry (Fig. 5). On MALDI-TOF
MS, singly protonated molecular ion (M+H)+ of the purified
LL-37 was observed at m/z 4492.4 Da while the calculated
molecular mass is 4493.3 Da. The eluted LL-37 was freeze-
dried with a bench top freeze dryer (VirTis, USA) and
dissolved in sterile PBS. The final yield of purified LL-37 per
liter of culture was ∼0.3 mg/l (Table 2). The total recovery of
the peptide was 7%. The apparent decrease in protein yield
after affinity chromatography using GSTrap FF column was
due to removal of the fusion partner. The decrease was alsopartly due to incomplete digestion of the GST-LL-37 fusion
protein by Factor Xa.
4. Discussion
Recently, antimicrobial peptides have been studied exten-
sively because of their possible clinical applications as agents for
the treatment of infective diseases. Among these antimicrobial
peptides, LL-37 is a very promising candidate because it
originates from human. The highly efficient production of
biologically active LL-37, with large quantity and low cost, is an
absolute need for both structure–function relationship investi-
gation and potential clinical applications. In particular, charac-
terization of the molecular mechanism of lipid bilayer disruption
by LL-37 is our final goal by employing solution and solid-state
NMR spectroscopy. Due to the need for large quantity of LL-37
for these studies, we sought a production method of LL-37
utilizing E. coli, as it yields a high level of pure and uniformly
labeled protein necessary for experimental studies. In the current
work, we constructed a highly efficient system for the expression
and purification of a human LL-37 in E. coli, using the pGEX-
4T3 expression vector with a tac promoter.
Fig. 5. MALDI-TOF MS analysis of the purified LL-37. MALDI-TOF MS analysis indicates that LL-37 has monoisotopic molecular mass of 4492.4 Da. The
corresponding doubly charged protonated molecule is at m/z 2247.5 Da.
1356 J.-Y. Moon et al. / Biochimica et Biophysica Acta 1758 (2006) 1351–1358There are no methods reported for the direct expression of
recombinant LL-37 so far. While our research was on progress,
Yang et al. [24] had reported the expression of a variant of LL-
37 that has two extra amino acid residues, Gly–Ser, in its N-
terminus. Since the activity of a peptide is sensitive to the exact
amino acid sequence, the presence of unnecessary Gly and Ser
residues could lead to biological activities that may differ from
that of LL-37. In our study, a fusion protein between GST and
LL-37 was produced from an E. coli strain harboring a
recombinant pGEX-4T3-LL-37 plasmid. The bacterial strain
was grown on M9-Amp minimal medium (glucose, MgSO4,
CaCl2, ampicillin) including
15NH4Cl, since this media contains
only one source carbon and nitrogen and will be used for
uniform labeling of isotope. Over expression of the GST-LL-37
construct did not limit the cell growth (OD595 nm of induced
cultures 1.0–1.3, uninduced was 1.3), indicating that GST is
able to sequester LL-37 and prevent it from killing the E. coli
host. The fusion protein was expressed into the cytoplasm
where it could be recovered following lysis of the bacteria.
Normally, recombinant fusion proteins should be cleaved to
release the peptide of interest for clinical and biological studies.
Factor Xa protease is one among of few proteases that permits
the release of the target protein without additional N-terminal
residues. In this study, we constructed the GST-LL-37 by
inserting Factor Xa cleavage site to cleave the LL-37 peptide
from the GST tag cleanly with no extra residues left attached to
the peptide. A Factor Xa recognition site between BamHI
restriction enzyme site and oligonucleotides encoding the 37
amino acid residues of LL-37 was inserted to correctly cleave
LL-37 peptide from GST-LL-37 fusion protein. The GST is a
soluble cytoplasmic protein, which is well established as a
useful partner for highly soluble and stable fusion proteins, used
in the expression of many biologically active mammalian
growth factors and cytokines in E. coli. This method of
releasing LL-37 using Factor Xa together with the high-levelexpression as a GST fusion protein readily constitutes a good
system for rapid production of LL-37. In our study, recombinant
LL-37 was directly and easily purified using the reverse-phase
HPLC after the enzymatic digests of GST-LL-37 fusion protein
with Factor Xa.
In our study, a relatively high amount of the recombinant
GST-LL-37 fusion protein was in soluble form, while some
amount of the fusion protein was also found in inclusion body.
The final yield of purified LL-37, 0.3 mg per liter of culture,
could be improved by increasing the solubility of GST-LL-37.
The expression and yield of the fusion protein were influenced
by the temperature of the culture during induction and by the
concentration of IPTG. In our preliminary study, we found that
culture of BL21(DE3) in the presence of 1.5 mM IPTG at 37 °C
resulted in the degradation of the GST-LL-37 fusion protein or
the formation of inclusion body, which was difficult to recover
(data not shown). We found that induction of the recombinant
GST-LL-37 fusion proteins, both unlabeled and labeled with
15N, at low temperature (30 °C) and low IPTG (0.1 mM)
concentration greatly improved the yield of intact soluble GST-
LL-37 fusion protein for all densities and induction times tested
(data not shown). Co-expression with molecular chaperones, TF
and GroEL–GroES [25–27], may play cooperative roles in
improving the solubility of GST-LL-37. The yield of the fusion
protein was also influenced by the presence of nonionic
detergent, Triton X-100, in cell lysate buffers. 1% Triton X-
100 in the extraction buffer greatly improved the recovery of
GST-LL-37 from E. coli (data not shown). It may be possible to
improve the yield using other recombinant procedures for
producing short cationic antimicrobial peptides in bacteria [28].
In summary, we constructed an efficient system for the
expression and purification of a LL-37 in E. coli, using the
pGEX-4T3 expression vector with a tac promoter. To the best of
our knowledge, it is the first report on the effective expression
and purification of intact and bioactive human LL-37. It was
1357J.-Y. Moon et al. / Biochimica et Biophysica Acta 1758 (2006) 1351–1358confirmed that the fusion expression system produced soluble
GST-LL-37 (LL-37 fused with GST) and that the recombinant
LL-37 peptide could be obtained from the fusion protein
through the enzymatic digestion with Factor Xa or thrombin.
The expression system and purification method of LL-37 will
be fully helpful in the structural and functional studies of LL-37.
In the near future, the availability of purified LL-37 could also
enable the clinical, structural, biochemical, and biological
investigations.
Amino acid selective and uniform labeling of LL-37 with
15N, 13C, 19F and/or 2H would enable a plethora of biophysical
studies (as reported in the literature [29–40]) to understand the
membrane–peptide interactions, peptide-induced changes in the
membrane, and the role of membrane composition. Studies to
determine the structural folding, oligomerization and dynamics
of LL-37 and its analogs in water versus membrane are in
progress in our laboratory using a variety of solid-state NMR
experiments.
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